Eli Lilly taps former US FDA official Peter Marks to head infectious disease

Eli Lilly has appointed Peter Marks, a former official from the US FDA, to lead its infectious disease division. This move is significant as Marks brings extensive experience in regulatory affairs and public health, which could enhance the company's efforts in developing treatments for infectious diseases. His leadership is expected to drive innovation and improve patient outcomes, making this a promising development for both Eli Lilly and the healthcare sector.